EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewsWire • 07/16/24
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/24
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 05/08/24
EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead ProgramSeeking Alpha • 05/07/24
EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goalMarket Watch • 05/06/24
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyGlobeNewsWire • 05/06/24
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsGlobeNewsWire • 04/02/24
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call TranscriptSeeking Alpha • 03/07/24
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 03/07/24
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 03/07/24
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerGlobeNewsWire • 03/04/24
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/29/24
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep goingZacks Investment Research • 02/29/24
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024GlobeNewsWire • 02/29/24
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 02/27/24
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great ChoiceZacks Investment Research • 02/15/24
Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a BetZacks Investment Research • 02/13/24
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular DegenerationGlobeNewsWire • 02/03/24
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24